Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma

Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma

Abstract Introduction Initially approved for the fifth‐line or later therapeutic setting, the chimeric antigen receptor (CAR) T‐cell regimen ciltacabtagene autoleucel (cilta‐cel) was recently approved for second‐line (2L) treatment in relapsed/refractory multiple myeloma (RRMM). Oncology practitione...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexandrina Balanean, Samuel Baird, Brooke Dulka, Luke Jennings‐Zhang, Robert N. Bone, Yolaine Jeune‐Smith, Bruce Feinberg, Muhamed Baljevic
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:eJHaem
Subjects:
CARTITUDE‐4
chimeric antigen receptor (CAR) T‐cell therapy
ciltacabtagene autoleucel
multiple myeloma
real‐world oncology practitioner perceptions
Online Access:https://doi.org/10.1002/jha2.1047
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jha2.1047

Similar Items